Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

NCT00051597 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00051597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
Not reported
Completion date
August 31, 2003
Enrollment
70
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, lymphoma, b-cell, lymphoma, large-cell, lymphoma, t-cell, cutaneous, sarcoma, kaposi